← Back to Search

Procedure

Harmonic Scalpel vs Electrocautery for Lung Cancer

N/A
Recruiting
Led By Joseph Newton, MD
Research Sponsored by Sentara Cardiovascular Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients undergoing resection for stage 1, 2 or 3A lung cancer
Patients between the ages of 20-75
Must not have
History of Congestive Heart Failure
History of renal failure, i.e., creatinine greater than 2.2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare the Harmonic Scalpel to a control group using electrocautery in order to determine which is more effective in minimizing drainage and length of stay.

Who is the study for?
This trial is for people aged 20-75 who are having lung cancer surgery (stage 1, 2 or 3A) and have not joined another study. It's not for those with kidney failure, heart failure, pregnant individuals, or stage 3A patients with bulky lymph nodes.
What is being tested?
The study compares the Harmonic Scalpel to electrocautery in lung cancer surgery. The goal is to see if the Harmonic Scalpel can better seal lymphatics to reduce drainage and potentially shorten hospital stays.
What are the potential side effects?
Potential side effects may include issues related to surgical procedures such as infection risk at the incision site, bleeding, pain or discomfort post-operation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lung cancer is at an early to mid-stage (1, 2, or 3A) and I am having surgery to remove it.
Select...
I am between 20 and 75 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of heart failure.
Select...
My creatinine levels are above 2.2, indicating kidney issues.
Select...
My cancer is at stage 3A with large or clustered lymph nodes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Group AActive Control1 Intervention
Electrocautery used for dissection.
Group II: Group BActive Control1 Intervention
Harmonic Scalpel used for dissection

Find a Location

Who is running the clinical trial?

Sentara Cardiovascular Research InstituteLead Sponsor
Ethicon Endo-SurgeryIndustry Sponsor
84 Previous Clinical Trials
36,025 Total Patients Enrolled
Joseph Newton, MDPrincipal InvestigatorSentara Cardiovascular Research Institute
~3 spots leftby Nov 2025